Sigma-Aldrich, Sangamo Expand Zinc Finger Tech License | GenomeWeb

NEW YORK (GenomeWeb News) – Sigma-Aldrich and Sangamo BioSciences today announced an expansion of their licensing deal covering zinc finger DNA binding protein-modified cell lines.

Under the new pact, Sigma-Aldrich gains exclusive rights to develop and distribute the ZFP-modified cell lines for commercial production of protein pharmaceuticals. In addition, Sigma-Aldrich has rights to certain ZFP-engineered transgenic animals for commercial applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.